ReviewJournal of biosafety and biosecurity2019
Current status and future challenges of high-level biosafety laboratories in China.
Review in Journal of biosafety and biosecurity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Global Patent Landscape and Technological Trends in Biosafety Level 3 (BSL-3) Laboratories Technologies.Biotech (Basel (Switzerland)) · 2026Article
- China's biosafety/biosecurity governance: evolution, challenges, and architecture design.Frontiers of medicine · 2025Article
- Biological Containment for African Swine Fever (ASF) Laboratories and Animal Facilities: The Italian Challenge in Bridging the Present Regulatory Gap and Enhancing Biosafety and Biosecurity Measures.Animals : an open access journal from MDPI · 2024Article
- Three Experimental Common High-Risk Procedures: Emission Characteristics Identification and Source Intensity Estimation in Biosafety Laboratory.International journal of environmental research and public health · 2023Article
- In the Shadow of Biological Warfare: Conspiracy Theories on the Origins of COVID-19 and Enhancing Global Governance of Biosafety as a Matter of Urgency.Journal of bioethical inquiry · 2020Article
- Biosafety and biosecurity approaches to restrain/contain and counter SARS-CoV-2/COVID-19 pandemic: a rapid-review.Turkish journal of biology = Turk biyoloji dergisi · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-level biosafety laboratories are safe and secure platforms which integrate reliable containment, well-trained personnel, and specific biosafety manuals and practices to protect researchers from being infected while manipulating microbial pathogens and prevent pathogens from being released into the outside environment. During the past decades, laboratories with different protection levels have been constructed and operated, the legal framework and a laboratory biosafety management system have been established, and these operational laboratories have played an essential role in combatting emerging and re-emerging infectious diseases in China. Here, we have summarized the significant achievements of high-level laboratory planning, construction, and operation in China, as well as the challenges that we face in the future. Additionally, we have briefly discussed the national plan for construction of high-level biosafety laboratories from 2016-2025 and "biosafety-motivated" management system. This review might be informative for further understanding the present situation and future function of high-level biosafety laboratories in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.